ASCO 2015 Highlights

The treatment of acute myeloid leukemia (AML) has entered a new era, with the use of more potent therapies, such as targeted agents and venetoclax (Venclexta). The advent of these newer therapies raises important issues that are yet to be clarified, said Daniel A. Pollyea, MD, MS, Clinical Director, Leukemia Services; Robert H Allen, MD Chair in Hematology Research; and Professor, Hematology, University of Colorado Blood Disorders and Cell Therapies Center, Anschutz, during a session on evolving concepts and management strategies for AML at the National Comprehensive Cancer Network (NCCN) 2022 Annual Congress: Hematologic Malignancies.

A survey of US physicians who prescribe biologics to their patients revealed that 92% were confident in the safety and efficacy of biosimilars, 89% would prescribe a biosimilar to a new patient, and 80% were comfortable initiating the switching of patients who are stable on their current biologic medication to a biosimilar. However, the majority of respondents indicated that they were not comfortable with third-party substitution for nonmedical reasons, and felt that they, along with their patients, should have control over treatment choice. Results of this survey were discussed by Ralph McKibbin, MD, FACP, FACG, AGAF, Chairman of the Alliance for Safe Biologic Medicines, in a poster presentation during the Drug Information Association 2022 Global Annual Meeting.

We review the latest clinical evidence from the phase 3 ICARIA-MM and IKEMA studies of isatuximab, an anti-CD38 mAb, in patients with RRMM. In addition, the cost implications of MM management and evolving approaches for mitigating the cost burden without compromising clinical outcomes for patients with MM are discussed.

The ICARIA-MM and IKEMA-MM phase 3 trials have been pivotal in identifying Isa’s high efficacy and favorable tolerability profile as a notable therapy in the role of RRMM management. Recently, there have been additional updates illustrating the unique effects of Isa. This article focuses on these updates and how they may inform the role of Isa in the treatment of MM.

The authors have discussed the cost drivers in myeloma therapy and have offered mitigating solutions, including pharmacy assistance programs and copay assistance, to help defray the financial burden on the patients.

In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

For this supplement, expert faculty provided detailed perspectives based on their extensive experience in the management of non–small cell lung cancer (NSCLC), focusing on the incorporation and importance of biomarker testing in precision medicine for improved patient care.

Although it is well established that air pollution is associated with lung cancer, how this occurs has not been well described. For the first time, researchers have identified the mechanism by which particulate matter in the air may lead to non–small-cell lung cancer (NSCLC) in people who have never smoked.